Immuron Ltd (IMRN) stock
Close on Nov 13, 2026Market cap $7.06MP/E –Yield –
Immuron Ltd grew revenue 5.9% to A$7.71M over fiscal 2026. Free cash flow was -A$3.26M. At the latest close the market valued the company at A$10.28M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026
Valuation
- Market cap
- A$10.28M
- P/E ratio
- –
- Price to sales
- 1.33
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -31.77%
Fundamentals
- Revenue
- A$7.71M
- Net income
- -A$3.68M
- EPS, diluted
- -1.24 AUD
- Free cash flow
- -A$3.26M
Trading
- Previous close
- $0.91
- Open
- $0.85
- Day's range
- $0.85 – $0.91
- Volume
- 16,128
- Average volume (20 days)
- 17,519
- Beta (5 years)
- 0.37
- RSI (14 days)
- 39.7
- Volatility (1 year)
- 107.1%
- Relative volume
- 0.01×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMRN | S&P 500 | Difference | IMRN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.8% | -3.0% | −12.8 pts | ||
| 3 months | -22.5% | -2.8% | −19.8 pts | ||
| Year to date | +14.8% | +11.5% | +3.3 pts | ||
| 1 year | -43.9% | +13.5% | −57.4 pts | ||
| 3 years | -48.5% | +77.7% | −126.2 pts | -19.9% | +21.1% |
| 5 years | -75.9% | +72.6% | −148.5 pts | -24.8% | +11.5% |
Twelve years at a glance
Fiscal years 2015 to 2026, AUD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Immuron filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Immuron
Pharmaceutical Preparations
Immuron Limited is an Australian biopharmaceutical company engaged in developing and commercializing orally delivered polyclonal antibody therapies targeting mucosal surfaces in the gastrointestinal tract. The company focuses on addressing conditions such as travelers' diarrhea, irritable bowel syndrome, and enteric infections caused by pathogens like Enterotoxigenic Escherichia coli and Clostridioides difficile. Its commercial offerings include Travelan, an over-the-counter formulation designed to lower the incidence of travelers' diarrhea, and ProIBS, an orally administered product containing AVH200 that creates a protective hydrogel barrier to soothe irritable bowel syndrome symptoms. Operating across hyper-immune products and research and development divisions, the business primarily supplies retail consumers and travel health markets through retail pharmacies, clinical practitioners, and online channels.
Company profile, executives and historyImmuron stock: common questions
What is Immuron's stock price?
IMRN closed at $0.88 on Nov 13, 2026, down 3.52% on the day.
What is Immuron's market cap?
Immuron was worth $7.06M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is IMRN's P/E ratio?
Immuron lost money over fiscal 2026 (diluted EPS -1.24 AUD), so it has no meaningful P/E ratio.
How much revenue does Immuron make?
Immuron reported revenue of A$7.71M for fiscal 2026, up 5.9% from a year earlier.
Does Immuron pay a dividend?
No. Immuron has not paid a cash dividend over the last twelve months.
How has IMRN stock performed over the past year?
Including dividends, IMRN returned -43.9% over the past year, against +13.5% for the S&P 500.
Who are Immuron's competitors?
Companies most similar to Immuron by business, industry and size include RANI, ALMS, ISCO, APLM, EVMN.
See a number that looks wrong?